The Top 5 Biosimilars Articles for the Week of February 17

February 21, 2020

The Center for Biosimilars® recaps the top stories for the week of February 17, 2020.

Hi, I’m Christina Mattina for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilars articles for the week of February 17, 2020.

Number 5: A new review article discusses the data relevant to inflammatory bowel disease on biosimilars for anti—tumor necrosis factor inhibitors and urges physicians to consider anti-TNF biosimilars for patients with IBD.

Number 4: Which Medicaid plans benefit the most from benefit from the current drug rebate structure and are incentivized to prescribe branded prescriptions? Researchers used the cost issue of follow-on insulin glargine as well as glatiramer acetate to find out.

Number 3: A crossover study comparing autoinjector and prefilled syringe delivery methods of etanercept biosimilar SB4 shows bioequivalent pharmacokinetic parameters and similar safety profiles following a single administration in healthy men.

Number 2: A pharmaceutical industry veteran and consultant for biosimilar makers discusses the ins and outs of the approvals process that cause frustration and unnecessary expense at the recent Specialty Therapies and Biosimilars Congress.

Number 1: Hurdles to a vibrant biosimilar market are not as insurmountable as they appear, according to Center for Biosimilars contributor Steven Lucio, the associate vice president for the Center for Pharmacy Practice Excellence at Vizient.

To read all of these articles and more, visit centerforbiosimilars.com.